OPEN MARKET SALE AGREEMENTSMCRISPR Therapeutics AG • August 30th, 2019 • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • August 31st, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York
INCENTIVE STOCK OPTION AGREEMENT UNDER THE CRISPR THERAPEUTICS AGIncentive Stock Option Agreement • June 1st, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.
EMPLOYMENT AGREEMENTEmployment Agreement • March 14th, 2023 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made as of the 14th day of March, 2023 between CRISPR Therapeutics, Inc., a Delaware corporation (the “Company”), and Raju Prasad (the “Executive” and, together with the Company, the “Parties” or each individually, a “Party”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 7th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This Indemnification Agreement (“Agreement”) is made as of by and between CRISPR Therapeutics AG, a Swiss stock corporation (the “Company”), and (“Indemnitee”).
NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AGNon-Qualified Stock Option Agreement • June 1st, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AG AMENDED AND RESTATED 2016 STOCK OPTION AND INCENTIVE PLANNon-Qualified Stock Option Agreement • November 8th, 2017 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG Amended and Restated 2016 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
CRISPR THERAPEUTICS AG 6,428,572 Common Shares (nominal value CHF 0.03 per share) Underwriting AgreementCRISPR Therapeutics AG • July 2nd, 2020 • Biological products, (no disgnostic substances) • New York
CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Issuer”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 6,428,572 common shares, nominal value CHF 0.03 per share (“Common Shares”), of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to 964,285 additional Common Shares (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requir
INCENTIVE STOCK OPTION AGREEMENT UNDER THE CRISPR THERAPEUTICS AG AMENDED AND RESTATED 2016 STOCK OPTION AND INCENTIVE PLANIncentive Stock Option Agreement • November 8th, 2017 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG Amended and Restated 2016 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.
INCENTIVE STOCK OPTION AGREEMENT UNDER THE CRISPR THERAPEUTICS AGIncentive Stock Option Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.
NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AGNon-Qualified Stock Option Agreement • June 1st, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
NON-QUALIFIED STOCK OPTION AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AGNon-Qualified Stock Option Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AGRestricted Stock Unit Award Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company.
STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED VERTEX PHARMACEUTICALS (EUROPE) LIMITED AND CRISPR THERAPEUTICS AG CRISPR THERAPEUTICS LIMITED CRISPR THERAPEUTICS, INC. TRACR HEMATOLOGY LTD.Collaboration, Option and License Agreement • October 7th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
This STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 26, 2015 (the “Effective Date”) by and between, on the one hand, VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of The Commonwealth of Massachusetts (“Vertex Parent”), and VERTEX PHARMACEUTICALS (EUROPE) LIMITED, a private limited liability company organized under the laws of England and Wales (“Vertex UK” and, together with Vertex Parent, “Vertex”) and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (“CRISPR AG”), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (“CRISPR UK”) and TRACR HEMATOLOGY LTD, a UK limited company (“Tracr” and together with CRISPR AG, CRISPR Inc. and CRISPR UK “CRISPR”). Vertex and CRISPR each may be referred to herein
LICENSE AGREEMENTLicense Agreement • October 7th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • England
THIS LICENSE AGREEMENT (“Agreement”) is entered into and effective as of April 10, 2014 (the “Effective Date”), by and between EMMANUELLE MARIE CHARPENTIER, an individual residing at Böcklerstrasse 18, 38102 Braunschweig, Germany (“EC”), and TRACR HEMOGLOBINOPATHIES LTD, a UK limited company having its registered office at 90 Fetter Lane, London EC1A 1JP, United Kingdom (“Tracr”).
LICENSE AGREEMENTLicense Agreement • October 7th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • England
THIS LICENSE AGREEMENT (“Agreement”) is entered into and effective as of April 15, 2014 (the “Effective Date”), by and between EMMANUELLE MARIE CHARPENTIER, an individual residing at Böcklerstrasse 18, 38102 Braunschweig, Germany (“EC”), and CRISPR THERAPEUTICS AG, a company organized under the laws of Switzerland having a principal place of business at Aeschenvorstadt 36, CH-4051 Basel, Switzerland (“CRISPR”).
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR COMPANY EMPLOYEES UNDER THE CRISPR THERAPEUTICS AGRestricted Stock Unit Award Agreement • June 1st, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company.
RESTRICTED STOCK UNIT AWARD AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AGRestricted Stock Unit Award Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company.
AMENDMENT NO. 1 TO THE AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENTJoint Development and Commercialization Agreement • December 13th, 2023 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This AMENDMENT NO. 1 TO THE AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Amendment”) is entered into as of December 12, 2023 (the “Amendment Effective Date”) by and between, on the one hand, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of The Commonwealth of Massachusetts, and Vertex Pharmaceuticals (Europe) Limited, a private limited liability company organized under the laws of England and Wales (together, “Vertex”) and, on the other hand, CRISPR Therapeutics AG, a corporation organized under the laws of Switzerland, CRISPR Therapeutics, Inc., a corporation organized under the laws of the state of Delaware, CRISPR Therapeutics Limited, a corporation organized under the laws of England and Wales, and TRACR Hematology Ltd, a UK limited company (collectively, “CRISPR”). Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.” This Amendment amends the Amended
CRISPR IP CONTRIBUTION AGREEMENTCrispr Ip Contribution Agreement • July 8th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York
This CRISPR IP Contribution AGREEMENT (this “Contribution Agreement”) is entered into as of March 16, 2016 (the “Effective Date”) by and between, on the one hand, VIVR LLP, a limited liability partnership duly incorporated under the laws of England and Wales (“Company”), and, on the other hand, CRISPR THERAPEUTICS AG, a corporation organized under the laws of Switzerland (“CRISPR AG”), CRISPR THERAPEUTICS, INC., a corporation organized under the laws of the state of Delaware (“CRISPR Inc.”), CRISPR THERAPEUTICS LIMITED, a corporation organized under the laws of England and Wales (“CRISPR UK”) and TRACR HEMATOLOGY LTD, a UK limited company (“TRACR” and together with CRISPR AG, CRISPR Inc. and CRISPR UK “CRISPR”).
CONSENT TO SUBLEASESublease Agreement • July 27th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
THIS CONSENT TO SUBLEASE (this “Consent”), dated as of May 16, 2016, is entered into by and among MIT 650 MAIN STREET LLC, a Massachusetts limited liability company (“Prime Landlord”), PFIZER INC., a Delaware corporation (“Sublandlord”) and CRISPR THERAPEUTICS, INC., a Delaware corporation (“Subtenant”).
JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED VERTEX PHARMACEUTICALS (EUROPE) LIMITED AND CRISPR THERAPEUTICS AG CRISPR THERAPEUTICS LIMITED CRISPR THERAPEUTICS, INC. TRACR HEMATOLOGY LTD.Joint Development and Commercialization Agreement • December 18th, 2017 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
[***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ASSIGNMENT OF SUBLEASE AND SUB-SUBLEASEAssignment of Sublease and Sub-Sublease • February 12th, 2020 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
This ASSIGNMENT OF SUBLEASE AND SUB-SUBLEASE (this “Assignment”) is made as of December 13, 2019 by and between Casebia Therapeutics LLC (“Assignor”) and CRISPR Therapeutics, Inc. (“Assignee”).
RESTRICTED STOCK AWARD AGREEMENT UNDER THE CRISPR THERAPEUTICS AGRestricted Stock Award Agreement • June 1st, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator.
EMPLOYMENT AGREEMENT made as of October 6, 2016 betweenEmployment Agreement • October 7th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
WHEREAS, with the completion of the contemplated initial public offering of the Company (“IPO”), the Company will subject to the Swiss act against excessive remunerations by listed companies;
REGISTRATION RIGHTS AGREEMENT made as of June 10, 2016 by and amongRegistration Rights Agreement • September 9th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
WHEREAS, the Initial Holders are holders of the Company’s Preferred Shares and/or Common Shares issued upon the conversion thereof; and
CRISPR THERAPEUTICS AG Common Shares (nominal value CHF 0.03 per share) Underwriting AgreementCRISPR Therapeutics AG • October 7th, 2016 • Biological products, (no disgnostic substances) • New York
CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Issuer”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, [●] common shares, nominal value CHF 0.03 per share (“Common Shares”), of the Issuer (said shares to be issued and sold by the Issuer being hereinafter called the “Underwritten Securities”). The Issuer also proposes to grant to the Underwriters an option to purchase up to [●] additional Common Shares to cover over-allotments, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural
AMENDMENT NO. 1 TO THE STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENTOption and License Agreement • December 18th, 2017 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
This Amendment No. 1 to the Strategic Collaboration, Option and License Agreement, dated October 26, 2015, between Vertex Pharmaceuticals Incorporated (“Vertex Parent”) and Vertex Pharmaceuticals (Europe) Limited (“Vertex UK” and together with Vertex Parent, “Vertex”), on the one hand, and CRISPR Therapeutics AG (“CRISPR AG”), CRISPR Therapeutics, Inc. (“CRISPR Inc.”), CRISPR Therapeutics Limited (“CRISPR UK”) and TRACR Hematology Ltd (“Tracr” and together with CRISPR AG, CRISPR Inc. and CRISPR UK “CRISPR”), on the other hand (this “Amendment”) is entered into as of this 12th day of December, 2017 (the “Amendment Effective Date”) by and between Vertex and CRISPR. Capitalized terms used and not defined herein have their respective meanings set forth in the Agreement (as defined below).
Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential. Certain exhibits and schedules to these agreements have been omitted...Non-Exclusive License Agreement • March 27th, 2023 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • Massachusetts
This NON-EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of March 23, 2023 (the “Effective Date”) by and between Vertex Pharmaceuticals Incorporated (“Vertex”) and CRISPR Therapeutics AG (“CRISPR”). Vertex and CRISPR each may be referred to herein individually as a “Party” or collectively as the “Parties.”
CRISPR Therapeutics AG (the Company )Mandate Agreement • December 27th, 2019 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
The Parties take note that Dr. Rodger Novak (the Advisor) has been acting as the chairman of the Company’s board of directors (the Chairman and the Company’s board of directors the Board) since his election at the 2018 general meeting of shareholders of the Company. The Advisor has not received any remuneration for his services as Chairman so far.
RE: Lease (the “Lease”) dated as of July 24, 2020, between 105 W. First Street Owner, L.L.C. (the “Landlord”) and CRISPR Therapeutics, Inc. (the “Tenant”)CRISPR Therapeutics AG • February 15th, 2022 • Biological products, (no disgnostic substances)
Reference is hereby made to the Lease. All capitalized words and phrases used in this letter agreement and not otherwise defined herein shall have the meanings ascribed to them in the Lease. The purpose of this letter agreement is to memorialize the agreement between Landlord and Tenant concerning the occurrence of certain delays in and adjustments to schedule for the performance of the Base Building Work and the Landlord’s Work, including the Scheduled Commencement Date and the Outside Delivery Date.
SUBSCRIPTION AGREEMENTSubscription Agreement • September 9th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made and entered into as of December 19, 2015 (the “Effective Date “), by and between CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) organized under the laws of Switzerland and registered under the registration number CHE-494.642.722 (the “Company”), Bayer Global Investments B.V., a Dutch private company with limited liability (Besloten vennootschap met beperkte aansprakelijkheid) (“Subscriber”).
NON-QUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS UNDER THE CRISPR THERAPEUTICS AGNon-Qualified Stock Option Agreement • March 8th, 2018 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
Pursuant to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), CRISPR Therapeutics AG (the “Company”) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value CHF 0.03 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.
EMPLOYMENT AGREEMENT effective as of December 1, 2017 (hereinafter referred to as the “Effective Date”) betweenEmployment Agreement • December 21st, 2017 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances)
WHEREAS, the Executive transitioned from his position as Chief Executive Officer of the Company to President of the Company effective as of the Effective Date (the “Position Change”);
SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN...Option Agreement • July 8th, 2016 • CRISPR Therapeutics AG • Biological products, (no disgnostic substances) • New York
THIS OPTION AGREEMENT (the “Agreement”) is made and entered into as of March 16, 2016 (the “Effective Date”), by and among, CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) organized under the laws of Switzerland and registered under the registration number CHE-494.642.722 (“CRISPR”), and Bayer HealthCare LLC, a limited liability company incorporated under the laws of Delaware (“Bayer”) and VIVR, LLP ,a limited liability partnership incorporated under the laws of England and Wales (“Company”). Bayer and CRISPR, collectively, are the “Optionees” and each, individually, is an “Optionee”. Terms not otherwise defined herein shall have the meaning set forth in that certain Joint Venture Agreement, dated as of December 19, 2015 (as amended, restated, or otherwise modified from time to time, the “JV Agreement”).
